Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S., Bernotas, A., Sharafshah, A., Blum, K., Posner, A., & Thanos, P
Food and Drug Administration rules under specific conditions
24.2% average weight loss at 48 weeks (12 mg dose) 91% of participants maintained weight without regain through week 48 28% nausea rate (lower than Wegovys 44%) 11.2% discontinuation rate due to side effects Emerging Research Directions Ongoing studies will better characterize the combination of bariatric surgery with newer GLP-1/GIP medications
Xing C, Zhao H, Zhang J, He B (2022) Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome
Tirzepatide also stands out when compared to other GLP-1 receptor agonists, such as semaglutide (Wegovy or Ozempic)
US$ 27.55
US$ 21.32
US$ 25.06
US$ 20.36
US$ 23.20
US$ 27.80
